A recent essay from Clinical Leader puts words to something our industry has felt but rarely articulates so directly: medical affairs, the author argues, is the missing link that turns oncology evidence into real adoption — and when we leave it on the periphery of development, we inadvertently raise the patient burden long before a drug ever reaches the bedside.
The External Lens Development Often Lacks
Drawing on a decade in oncology clinical development, the piece makes a case that should resonate with anyone who has watched a promising dataset gather dust in a journal. Clinical development already wrestles with patient selection, differentiation, positioning, and evidence requirements. The missing ingredient, the author suggests, is a continuous external perspective — the kind that practicing oncologists and scientific societies offer when they look at the same data and immediately ask where the drug would actually fit in an evolving treatment landscape, which patients would truly receive it, and whether the magnitude of benefit is enough to change practice.
Those questions carry particular weight in oncology, where the standard of care can shift while a molecule is still maturing in trials, molecularly defined subgroups can reshape the eligible population, and clinical value rests not only on antitumor activity but on the durability of benefit, toxicity profile, combination strategy, and the increasingly complex sequence in which therapies are deployed. Real-world evidence, the essay reminds us, adds another dimension here, illuminating patient populations, treatment patterns, outcomes, and the practical experience of using a drug beyond the controlled environment of a trial.
When That Lens Is Absent, the Consequences Surface Quickly
That is not a theoretical risk. The U.S. FDA placed a partial clinical hold on Biohaven's focal epilepsy candidate opakalim, known as BHV-7000, on September 4, pausing new patient enrollment after a metabolite flagged in rodent testing raised questions regulators felt were not yet resolved for human risk. Biohaven voluntarily extended the enrollment pause to sites outside the United States, while more than 600 patients already assigned to treatment continue to receive the drug, and one fully enrolled late-stage trial remains on track to report in the second half of 2026.
It is precisely the kind of moment where medical affairs — with its relationships across KOLs, practicing physicians, scientific societies, and patient advocacy groups — could have been framing the conversation earlier: helping sponsors anticipate which safety questions external reviewers would press on, contextualizing rodent findings against the lived experience of patients living with refractory focal epilepsy, and shaping the evidence-generation strategy while there is still time to influence it.
What We Carry Forward
We find ourselves returning to the essay's simplest claim, because it reframes the room: medical affairs should not be viewed as a supportive function but as an equal strategic partner across the development life cycle. For our colleagues weighing pipeline decisions, that distinction matters because it changes who is at the table when the most consequential questions get asked. The next time we hear of a regulatory pause or a stalled launch, it is worth asking whether the external clinical perspective arrived early enough to matter — and whether the patient, waiting for a meaningful new option, was kept at the center of every decision along the way.